Prana Biotech says EMA panel adopts positive opinion on Huntington's candidate; Australia's Benitec doses fifth patient in hep C trial;

> Prana Biotechnology said the European Medicines Agency's Committee for Orphan Medicinal Products has adopted a positive opinion recommending designation of PBT2 for the treatment of Huntington's disease. Release

> Benitec Biopharma said the fifth patient in the company's "first in man," Phase I/IIa dose escalation clinical trial of TT-034 for hepatitis C virus infection was dosed this week at the Duke Clinical Research Unit. Release (sub. req.)

> Janssen Biotech plans to appeal after the U.S. patent office notified it maintained its rejection of a Remicade patent. Separately, South Korea-based Celltrion says it plans to launch its biosimilar version, Remsima, in the U.S. by the end of this year. Release